Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

製品コードS1098 別名：PF-01367338

CAS No. 459868-92-9

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 24200
5mg	JPY 21900
10mg	JPY 36800
50mg	JPY 113200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(108)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

特性

The first PARP inhibitor used in clinical trials combined with temozolomide.

ターゲット

PARP ^[1]
(Cell-free assay)

1.4 nM(Ki)

体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. ^[1] ^[2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. ^[3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BT-474	Mm\oSpVv[3Srb36gRZN{[Xl?	MofMNE4yNzFxNUCwM\|ExODBibl2=			NIm3V3FqdmirYnn0d{BRSVKSIHHjeIl3cXS7IHH0JJN1[XK2aX7nJINwdmOncn70doF1cW:wIH;mJFUxOCCwTR?=	MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
BT474	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUe1NFAhdk1?	NGK5TogyOOLCk{G1xsBl		M4jS[pJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{OES1OUc,OjVzMki0OVU9N2F-
SKBR3	NH32bVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S1S\|UxOCCwTR?=	MofRNVDjiJNzNdMg[C=>		NYLPfohKemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>?	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
AU565	NGT5UFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7yOVAxKG6P	MX:xNQKBmzF3wrDk		MX\y[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC\|aXfubYZq[2GwdHz5	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
EFM192A	M3HOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK2WZY2ODBibl2=	NX3XS\|NCOTEkgKOxOeKh\A>?		NGXCO5dz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6	NVXLVG51RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
MDA-MB-231	Mm\sSpVv[3Srb36gRZN{[Xl?	M{HYVlExNzJyL{SwJO69VQ>?	MX:yOEBp		M1zuVolv[3KnYYPld{BxNUGNVDDs[ZZmdHNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NGXITmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231	Mn\zR4VtdCCYaXHibYxqfHliQYPzZZk>	NX3NbXQ5OC5zLUSwJO69VQ>?	NYXEXWRtOjRiaB?=		MVvJR\|Ux6oDLPfMAjVE4Njd5wrFOwG0>	M1zqb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKwNVUzLz5{NESyNFE2OjxxYU6=
MDA-MB-231	NVq1R2pUSXCxcITvd4l{KEG\|c3H5	MmrENVAwOjBxNECg{txO	NYe5UpBHOjRiaB?=		MUnpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NWrhUYp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlAyPTJpPkK0OFIxOTV{PD;hQi=>
MDA-MB-231	MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W0d\|ExNzJyL{SwJO69VQ>?	NXr4NIczOjRiaB?=		NF3LflZjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCrbjDHNk9OKHCqYYPl	NIS3e3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
H460	M{HIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPqTII1ODBibl2=	NYTVNFVmOjUEoHi=		M1LZNIlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMU[xNUc,OjR2MUG2NVE9N2F-
A549	NUfnO29VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn3OFAxKG6P	MnnHNlTDqGh?		MojrbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMU[xNUc,OjR2MUG2NVE9N2F-
DT40	NY\6OoFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mon0TWM2OD1{MTDuUS=>	Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
DU145	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\XTWdKSzVyPUG4JI5O	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3NkixN{c,OjR\|NU[4NVM9N2F-
COLO704	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLNe4hKSzVyPUKuOVIhyrFiMD62O{DPxE1?	NUXYOoJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OVMANAb	M3nHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJwNUigxtEhOC5\|ODFOwG0>	M3;YNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV177	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fGWWlEPTB;Mj63PEDDuSByLkexJO69VQ>?	MnLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OAW28	NH7iSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTCTWM2OD1\|Lk[xJOKyKDBwMkig{txO	NHT6SHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVSAHO	NGHqZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\4SZlKSzVyPUOuOlQhyrFiMD6zN{DPxE1?	MojlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OVKATE	M1XEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjHd41KSzVyPUOuOlQhyrFiMT63PUDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCAR3	M3u5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkizTWM2OD1\|Lke0JOKyKDBwNECg{txO	M2O1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
PEO14	NIf4TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTNwOESgxtEhOC55NjFOwG0>	NUO0cYl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
A2780	NWXzV3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXFU4xKSzVyPUOuPVQhyrFiMD6yOUDPxE1?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVTOKO	NFvGfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXOO5Y6UUN3ME20MlE1KMLzIEGuOVMh\|ryP	M{XBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KURAMOCHIb	M4Dwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HSZ2lEPTB;ND6zOEDDuSByLkK5JO69VQ>?	NYOzeHBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
TOV21G	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PYdmlEPTB;NT6wO{DDuSBzLkOwJO69VQ>?	MmTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OVISE	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HoT2lEPTB;NT62PEDDuSByLkKzJO69VQ>?	M1fmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KK	NIryWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXVTWM2OD14LkG1JOKyKDFwNEKg{txO	NHmyOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
RMUGS	NV\PU3U2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofiTWM2OD15LkCzJOKyKDFwOEOg{txO	MnvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
PEO6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\P[2tzUUN3ME23MlA3KMLzIECuO\|Qh\|ryP	NFrsOI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA429	M1;qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vVNWlEPTB;OD6yPUDDuSBzLk[0JO69VQ>?	NGHWWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV167	M2DyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX60ZotKUUN3ME24MlM{KMLzIEGuNVgh\|ryP	M1HlOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
RMG1	M4jqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\UTWM2OD17LkOyJOKyKDJwM{[g{txO	MkjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OVCAR5	NEThe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInGb21KSzVyPUmuOVAhyrFiMj61PUDPxE1?	M4DDUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
EFO21	NWrCSnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LoXGlEPTB;OT65NkDDuSBzLki3JO69VQ>?	NXT3eppNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
ES2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHryUnBKSzVyPUGwMlEzKMLzIEGuNlMh\|ryP	MnHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
Tyk-nu	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITjdnhKSzVyPUGwMlIxKMLzIEGuNVIh\|ryP	MoLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
CAOV3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfCTWM2OD1zMD6zO{DDuSByLki3JO69VQ>?	NFvjPYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV207	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofITWM2OD1zMj6yO{DDuSByLkOyJO69VQ>?	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
HEY	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfNTWM2OD1zMz6wNUDDuSByLke1JO69VQ>?	MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
DOV13	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDkOW1KSzVyPkG1JO69VQ>?	M2jVZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
EFO27	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRjF3IN88US=>	NU\t[Jl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
HEY C2	NU\qTlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkS5TWM2OD5zNTFOwG0>	NFPrUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
KOC-7cc	NXrYdoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\4WXN5UUN3ME6xOUDPxE1?	M2O4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
MCASb	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRjF3IN88US=>	NV;rdHVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
OAW42	NX\OTG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[ybGlEPTB-MUWg{txO	M1TrOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV2008	M4jweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDqTWM2OD5zNTFOwG0>	MnzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ\|N{K5OFAzRC:jPh?=
OV90	NHXmbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7U[4ZSUUN3ME6xOUDPxE1?	M3TUcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVCA420b	M1HYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\XTWM2OD5zNTFOwG0>	NGG1O4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCA432	NVnrUWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRjF3IN88US=>	NXPROIpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO\|I6PDB{PD;hQi=>
PEA2	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRjF3IN88US=>	NInjfXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
SKOV3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLpTWM2OD5zNTFOwG0>	M2PaTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
TOV112D	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXuwMVMh\|ryP			M2Do[WlEPTB-MUWg{txO	M3m4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
C4-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6wMVMh\|ryP	M{LYXFE1KGR?	MYTEUXNQ	M2[2NoRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl?	MkHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkWyOFQoRjJ\|NU[1NlQ1RC:jPh?=
PC3	M32yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKwMVMh\|ryP	MX:xOEBl	NUfx[o1rTE2VTx?=	NFXvdmNl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7	NIXpSoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
DU145	NGjWR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi3RodwOC1\|IN88US=>	MVyxOEBl	NHXkbIZFVVOR	M3q3coRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl?	NViy[FVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
VCaP	NXuwepN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1z1NVAuOyEQvF2=	NWXWNGE1OTRiZB?=	Mm\WSG1UVw>?	Mlz1[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>?	NUHtO4FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
LNCaP	NIG1UWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[wMVMh\|ryP	M4C3V\|E1KGR?	MUfEUXNQ	NFfr[Vll\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7	NIDVWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
MDA-MB-468	NF3DXlBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?				MYHJR\|UxRTlwNzFOwG0>	NXvlS4p5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2O\|gyPjFpPkKyOlc5OTZzPD;hQi=>
MDA-MB-231	MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				M1fY[GlEPTB;MUOg{txO	NIPrd4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O\|gyPjF:L3G+
Cal-51	M1rPZWNmdGxiVnnhZoltcXS7IFHzd4F6				MnPlTWM2OD16Lk[g{txO	M2fYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nke4NVYyLz5{Mk[3PFE3OTxxYU6=
LoVo	MnfPSpVv[3Srb36gZZN{[Xl?		NV;uOGJGOzBibXnudy=>		M{TFPWlvcGmkaYTpc44hd2ZiUFHSVEBqdiCqdX3hckBNd1[xIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheG:ueTjBSHAqNXKrYn;z[UBxd2y7bXXybZpifGmxbjDmc5IhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFXDOVAhRSByLkCwOFY6KM7:TT6=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkexO{c,OjZ4NUK3NVc9N2F-
MX1	M3XWO2N6fG:2b4jpZ4l1gSCjc4PhfS=>				MkXFR5l1d3SxeHnjbZR6KGGpYXnud5QhSlKFQUGt[IVncWOrZX70JIh2dWGwIF3YNUBk\WyuczygSWM2OCB;IECuNFA2OyEQvF2u	M3TGdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO\|E4Lz5{Nk[1NlcyPzxxYU6=
Rosetta2 (DE3)	Ml33SpVv[3Srb36gZZN{[Xl?				MoraTY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKD[6aHnzMZRi\2enZDDBVnRFPiBqOEezJJRwKDFzNkGpJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKFKxc3X0eIEzKCiGRUOpJINmdGy\|IIXzbY5oKE6DRDugZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFE1KM7:TT6=	M4ixfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|cxLz5{NEmwNFc4ODxxYU6=
Rosetta2 (DE3)	NWnNUW55TnWwY4Tpc44h[XO\|YYm=				NVS3UXB4UW6qaXLpeIlwdiCxZjDoeY1idiB4eHjpd{11[WepZXSgRXJVTDViKEGwN\|AhfG9iMUOxO{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliUn;z[ZR1[TJiKFTFN{kh[2WubIOgeZNqdmdiTlHEL{BieyC\|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOjVizszNMi=>	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3O\|AoRjJ2OUCwO\|cxRC:jPh?=
LoVo	NIXyZVlEgXSxdH;4bYNqfHliYYPzZZk>	NVu1fYF1OC52IIXN	NVvTdZpMPSCmYYnz		M325RXBwfGWwdHnheIlwdiCxZjD0[Y1wgm:ub33p[IUucW6mdXPl[EBkgXSxdH;4bYNqfHliaX6gbJVu[W5iTH;Wc{Bk\WyuczDhd5Nme3OnZDDhd{B1\W2xen;sc41q\GViR1m1NEBifCByLkSgeW0h[W[2ZYKgOUBl[Xm\|IHL5JGNmdGy2aYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjF2NDFOwG0v	MlTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO\|E4RC:jPh?=
Capan1	NFjDRplEgXSxdH;4bYNqfHliYYPzZZk>				M1zFdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GyMYRm\mmlaXXueEBpfW2jbjDDZZBidjFiY3XscJMtKEWFNUCgQUAxNjZyOTFOwG0v	MoiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO\|E4RC:jPh?=
MDA-MB-436	MnjjRY51cWOjbnPldkBie3OjeR?=		NInoOIc6PiCqcoO=		M3HB[mFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCVmNCOS2mZX\pZ4lmdnRiTVTBMW1DNTR\|NjDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOyEQvF2u	NUX0W5hURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOFI5PjhpPkK2N\|QzQDZ6PD;hQi=>
OVCAR3	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVqyOEBpenN?		MnjaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCRVlPBVlMh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOuN\|Eh\|ryPLh?=	NUXobJVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVYyODZpPkK5OFU3OTB4PD;hQi=>
MRC5	NXjTUYNUS3m2b4TvfIlkcXS7IHHzd4F6				NGfOUWNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{NCCHQ{WwJF0hQC53MzFOwG0v	NUniboI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
MCF7	M3fxWGFvfGmlYX7j[ZIh[XO\|YYm=		MkO2PVYhcHK\|		MYLBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDDR\|UxKD1iMUmuOFch\|ryPLh?=	NHXRSFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0Nlg3QCd-Mk[zOFI5Pjh:L3G+
A673	M2H6O5FJXFNiYYPzZZk>				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M4OwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MUTxTHRUKGG\|c3H5				NFHhUHNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	M{\ZRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NIrmeXJyUFSVIHHzd4F6				MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	MmW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NF;nPGpyUFSVIHHzd4F6				MkXvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	M16zflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NFnkeGZyUFSVIHHzd4F6				M121d5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	BRCA1; PubMed: 24085845 Proc Natl Acad Sci U S A MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. PAR; PubMed: 27960087 Cancer Cell MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.	24085845 27960087
Growth inhibition assay	Cell viability; PubMed: 31119062 Adv Wound Care (New Rochelle) The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.	31119062
Immunofluorescence	53BP1; PubMed: 23565244 PLoS One 53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. γH2AX; PubMed: 23565244 PLoS One γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. PAR; PubMed: 27515310 BMC Cancer Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown. α-tubulin; PubMed: 30589644 J Clin Invest Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm.	23565244 27515310 30589644

体内試験

Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. ^[4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. ^[5]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 K_i Determination: Inhibition of human full-length recombinant PARP-1 by [³²P]NAD⁺ incorporation is measured. The [³²P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. K_i is calculated by nonlinear regression analysis.
細胞試験： ^[4]	- 合併細胞株： D425Med, D283Med and D384Med cells 濃度： 0.4 μM 反応時間： 3 or 5 days 実験の流れ： Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 10³, 3 × 10³ and 3 × 10³, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone. (参考用のみ)
動物試験：^[4]	- 合併動物モデル： CD-1 nude mice bearing established D283Med xenografts 投薬量： 1 mg/kg 投与方法： One or four daily by i.p. (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.35 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

分子量	421.36
化学式	C₁₉H₁₈FN₃O.H₃PO₄
CAS No.	459868-92-9
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	PF-01367338
Smiles	CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04539327	Recruiting	Drug: Rucaparib	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Cancer	Grupo Español de Investigación en Cáncer de Ovario\|Clovis Oncology Inc.	July 29 2020	--
NCT04179396	Active not recruiting	Drug: Rucaparib\|Drug: Enzalutamide\|Drug: Abiraterone	Metastatic Castration Resistant Prostate Cancer	Clovis Oncology Inc.	December 5 2019	Phase 1
NCT04171700	Recruiting	Drug: Rucaparib	Solid Tumor	Clovis Oncology Inc.	November 21 2019	Phase 2
NCT03824704	Terminated	Drug: Rucaparib\|Drug: Nivolumab	Epithelial Ovarian Cancer\|Fallopian Tube Cancer\|Primary Peritoneal Carcinoma\|High Grade Serous Carcinoma\|Endometrioid Adenocarcinoma	Clovis Oncology Inc.\|Bristol-Myers Squibb\|Foundation Medicine	August 23 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.

相関PARP製品

G007-LK

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025

NU1025 (NSC 696807) is a potent PARP inhibitor with IC50 of 400 nM.
Blasticidin S HCl

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Olaparib (AZD2281)

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Features:A potent PARP inhibitor (currently in late stage clinical trials).
Veliparib (ABT-888)

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Talazoparib (BMN 673)

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

研究分野別

製品類型

Rucaparib (AG-014699) phosphate

文献中Selleckの製品使用例(108)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Rucaparib (AG-014699) phosphate SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技術サポート

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品